"The founders and teams running these Tech Companies to Watch deserve kudos for all of their incredibly hard work.” – Ryan Landau, founder and CEO, Purpose Jobs
ANN ARBOR, Mich. (PRWEB) January 10, 2023
Genomenon Inc., an AI-driven genomics company, has been named one of the Top Tech Companies to Watch in 2023 in Midwest tech by Purpose Jobs, the region's largest startup and tech community. The list, which includes companies headquartered and hiring in cities such as Ann Arbor, Chicago, Cincinnati, Cleveland, Columbus, Detroit, and more, recognizes companies based on notable company announcements including fundraising, partnerships, hiring, product development, and expansions.
“We are incredibly proud and honored to be recognized as one of the Top Tech Companies to Watch by Purpose Jobs in 2023,” said Mike Klein, CEO of Genomenon. "This recognition is a testament to the hard work and dedication of our team and the strong momentum we have established in the genomics market. At Genomenon, we are dedicated to excellence in everything we do and are proud of the milestones our company has achieved this past year. We are excited to see what the future holds for us in 2023."
In today's job market, with its economic uncertainty and widespread layoffs, professionals are looking for more than just a job – they are seeking out great cultures, growth opportunities, flexibility, and the chance to work in a purpose-driven environment. “We’re excited to keep an eye on these Tech Companies to Watch in 2023,” said Ryan Landau, founder and CEO of Purpose Jobs. “Despite a changing economic environment, there are still amazing stories of growth and success taking place in the world of tech and startups. The founders and teams running these Tech Companies to Watch deserve kudos for all of their incredibly hard work.”
To see the full list of recipients and learn more about the Top Tech Companies to Watch in 2023, visit the Purpose Jobs website.
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.
For more information, visit Genomenon.com